SCHEMBL2323540

SCHEMBL2323540

COc1cc(B2OC(C)(C)C(C)(C)O2)c(F)cc1NC(=O)c1cc2c(OC)cccc2n1C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
BRPF1 P55201 3/20 0.39
BRD4 O60885 1/20 0.39
ALDH1A1 P00352 5/20 0.38
MAPT P10636 4/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 1/20 0.38
ESR1 P03372 1/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 2/20 0.36
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2328721 0.84 KDM4E (0.49) KDM4EBRPF1BRD4ALDH1A1MAPT
SCHEMBL2323832 0.83 KDM4E (0.46) KDM4EBRPF1BRD4ALDH1A1MAPT
SCHEMBL2322997 0.79 KDM4E (0.46) KDM4EBRPF1BRD4ALDH1A1MAPT
SCHEMBL6433543 0.76 EGFR (0.35) KDM4EALDH1A1LMNATSHRKMT2A
SCHEMBL14118131 0.74 KDM4E (0.42) KDM4EALDH1A1MAPTHSD17B10LMNA
SCHEMBL12442144 0.73 KDM4E (0.49) KDM4EBRPF1BRD4ALDH1A1MAPT
SCHEMBL2326416 0.72 LCK (0.50) KDM4EMAPTLMNA
SCHEMBL5804731 0.71 AAK1 (0.39) ALDH1A1KMT2AMEN1
SCHEMBL2272984 0.71 KDM4E (0.51) KDM4EALDH1A1MAPTHSD17B10LMNA
SCHEMBL24746155 0.70 TSHR (0.52) KDM4EALDH1A1MAPTHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2534151-B1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MERCK SHARP & DOHME (NL) 2018-11-14 EP disclosed
US-8658794-B2 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof MERCK SHARP & DOHME B.V. (NL) 2014-02-25 US disclosed
EP-2534151-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS MSD Oss B.V. (NL) 2012-12-19 EP disclosed
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2012-12-06 US disclosed
WO-2011095556-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS N.V. ORGANON (NL) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309966-A1 8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS LCK, ZAP70, FYN KDM4E 329/4885BRPF1 3859/4885BRD4 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.